Arcus Biosciences, Inc.
RCUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | -0.39 | 0.01 | -0.39 |
| FCF Yield | -13.12% | -23.35% | 28.61% | -10.06% |
| EV / EBITDA | -4.65 | -4.46 | -5.44 | 47.04 |
| Quality | ||||
| ROIC | -35.38% | -37.61% | -24.33% | 3.65% |
| Gross Margin | -73.64% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.60 | 1.00 | -1.64 | -4.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 32.07% | -32.65% | 12.82% | 194.47% |
| Free Cash Flow Growth | 46.67% | -177.46% | 250.93% | -361.06% |
| Safety | ||||
| Net Debt / EBITDA | 0.33 | 0.40 | 0.33 | -0.53 |
| Interest Coverage | -82.50 | -170.00 | -140.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -621.63 | 131.03 | 140.13 | 709.99 |